3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Carcinoma, Non-Small-Cell Lung
103
Lung Neoplasms
44
Breast Neoplasms
41
Triple Negative Breast Neoplasms
34
Ovarian Neoplasms
28
Small Cell Lung Carcinoma
26
Squamous Cell Carcinoma of Head and Neck
23
Fallopian Tube Neoplasms
18
Endometrial Neoplasms
17
Neoplasms
16
Neoplasm Metastasis
13
Head and Neck Neoplasms
13
Uterine Cervical Neoplasms
12
Esophageal Squamous Cell Carcinoma
12
Prostatic Neoplasms
10
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Esophageal Neoplasms
10
Colorectal Neoplasms
9
Recurrence
8
Carcinoma, Transitional Cell
8
Oropharyngeal Neoplasms
7
Carcinoma, Squamous Cell
7
Neuroblastoma
6
Carcinoma, Ovarian Epithelial
6
Urinary Bladder Neoplasms
5
Mesothelioma
5
Lymphoma, Large B-Cell, Diffuse
5
Lung Diseases
5
Adenocarcinoma of Lung
5
Thoracic Neoplasms
4
Interventions
Fulvestrant
4
serabelisib
2
sapanisertib
2
ribociclib
2
palbociclib
2
tivozanib
1
pembrolizumab
1
olaparib
1
exemestane
1
abemaciclib
1
Tamoxifen
1
Secretin
1
STX-478
1
Radiotherapy
1
Pharmaceutical Preparations
1
Paclitaxel
1
Nivolumab
1
Metformin
1
Letrozole
1
Irinotecan
1
Imlunestrant
1
Gemcitabine
1
Carboplatin
1
CA-19-9 Antigen
1
Anastrozole
1
AZD1390
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hereditary Sensory and Autonomic Neuropathies
×
Carboplatin
×
Clear all
NCT04038502
2025-08-20
COBRA
VA Office of Research and Development
Phase 2
Recruiting
100 enrolled